Tumor necrosis factor (TNF)-alpha antagonists are a common treatment modality for autoimmune disorders, but their use can be associated with many side effects, including various dermatologic conditions. Certolizumab pegol, a newer TNF antagonist that lacks the Fc portion of the IgG antibody, has recently been approved to treat psoriatic arthritis, rheumatoid arthritis, and Crohn's disease. Though other TNF antagonists have been associated with leukocytoclastic vasculitis, this finding has not yet been reported with certolizumab pegol. We present a case report of leukocytoclastic vasculitis caused by certolizumab pegol. C ertolizumab pegol (CZP) is a pegylated, humanized, tumor necrosis factor (TNF)-alpha inhibitor that differs from other TNF-alpha inhibitors by being solely composed of a Fab fragment and lacking the Fc portion of the IgG antibody (1, 2) . By lacking the Fc portion, CZP cannot activate complement nor mediate antibody-dependent cell-mediated cytotoxicity; theoretically, this should reduce the potential for CZP to have Fc-mediated eff ects. While the other TNF-alpha antagonists have been cited to cause leukocytoclastic vasculitis (LCV), we believe this is the fi rst report of CZP causing LCV.
CASE PRESENTATION
A 28-year-old woman with Crohn's disease and ankylosing spondylitis presented for evaluation of a rash on her bilateral lower legs, feet, palms of hands, and plantar surface of her feet 6 months after beginning CZP. At age 26, she was diagnosed with severe ankylosing spondylitis; 6 months after diagnosis, she was placed on CZP as sole therapy. She received 400 mg of subcutaneous CZP every 4 weeks for approximately 1 year. She initially developed a rash after being on CZP for 6 months and remained on the CZP for an additional 6 months, due to the eff ective control of ankylosing spondylitis. Initially, many pruritic infl ammatory macules and papules involved the patient's legs and feet and extensive small vesicles were evident on the plantar surface of the patient's feet (Figure) . Several months after the initial presentation, the eruption extended to the patient's trunk and scalp, with the scalp lesions appearing as sebopsoriasis. Th e eruption progressed to include a folliculitis-like rash on the patient's thighs and arms. Th e patient additionally reported lower extremity edema with prolonged standing and lower leg muscle soreness.
Th e patient had documented intolerance for TNF-alpha inhibitors previously. At the initial diagnosis of Crohn's disease, she was treated with adalimumab but had intolerable side eff ects including alopecia, scalp psoriasis, severe hidradenitis of the groin and axillae, and vesicular eruption on her palms and soles. Adalimumab was thus discontinued and the patient subsequently underwent subtotal colectomy.
Th e patient underwent a punch biopsy of her left foot and right leg. Microscopic evaluation of the left foot demonstrated an unremarkable epidermis overlying dermal infi ltrates, composed mostly of neutrophils and scattered eosinophils. Chemotaxis of neutrophils leading to vessel wall injury, fi brin deposition, and erythrocyte extravasation along with fragmented neutrophils were also noted. Microscopic evaluation of the right leg infi ltrate to a mononuclear-predominant infi ltrate (7) . Furthermore, drug-induced LCV is often characterized as having an eosinophilic-predominant infi ltrate (8) . CZP is approved for treatment of psoriatic arthritis in many countries, including the US (1) . With the increasing use of CZP, physicians should be aware of this side eff ect and consider drug cessation if indicated.
